欧洲钱币状湿疹共识建议:改良德尔菲研究
钱币状湿疹(NE)缺乏临床指南,本研究通过两轮改良德尔菲法,由16国63名专家对64条陈述进行共识评估。49条(76.6%)达成共识,形成定义、诊断、患者评估和治疗四领域推荐,强调临床诊断和长期个体化治疗,并指出NE特异性评估工具和系统治疗随机试验的优先缺口。
要点
- 推荐临床诊断NE,并采用长期个体化治疗策略。
- endorsed治疗包括强效外用糖皮质激素、钙调神经磷酸酶抑制剂、外用JAK抑制剂、光疗及部分系统药物。
- 亟需开发NE特异性患者评估工具,并开展系统治疗的大样本随机试验。
核心结论
- 这是首个针对钱币状湿疹诊断和管理的专家共识推荐,提供实用且循证的指导。
- 优先缺口包括经过验证的NE特异性评估工具和系统治疗的随机试验。
研究设计与样本
- 科学委员会基于文献回顾和临床经验制定64条陈述,覆盖定义、诊断、患者评估和治疗四领域。
- 来自16个国家的63名专家(60名皮肤科医生和3名专科护士)通过两轮改良德尔菲法评估陈述。
主要发现
- 64条陈述中49条(76.6%)达成共识:定义领域7条中5条,诊断领域18条中11条,患者评估领域18条中15条,治疗领域21条中18条。
- 推荐强调临床诊断和长期个体化管理。
关键数值与推荐
- endorsed治疗包括强效外用糖皮质激素、钙调神经磷酸酶抑制剂、外用JAK抑制剂、光疗以及多数情况下超说明书使用的选定系统药物(用于难治性疾病)。
- 共识推荐强调需要开发和验证NE特异性患者评估工具,并开展大样本、设计良好的临床试验以确立系统治疗的疗效和安全性,以及定义特定的治疗反应目标。
临床怎么用
- 临床实践中可依据共识推荐进行NE的临床诊断和长期个体化治疗。
- 可选用强效外用糖皮质激素、钙调神经磷酸酶抑制剂、外用JAK抑制剂、光疗及选定系统药物(多数为超说明书使用)。
局限性
- 共识指出需开发经过验证的NE特异性评估工具,并开展系统治疗的大样本随机试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Nummular eczema (NE) is a chronic inflammatory skin disease characterized by intense pruritus, which can lead to sleep disturbance, reduced quality of life, and psychological distress. Despite its substantial burden on patients, there are currently no established clinical guidelines to support its diagnosis and management. OBJECTIVES: This study aimed to develop the first expert consensus-based recommendations for the definition, diagnosis, patient assessment and treatment of NE. METHODS: A Scientific Committee (SC) developed 64 statements across four domains-definition, diagnosis, patient assessment and treatment-based on a literature review and their own clinical expertise. A total of 63 experts (60 dermatologists and three specialist nurses) from 16 countries evaluated the statements via a two-round modified Delphi. Consensus was defined statistically, and statements reaching agreement informed the development of practical, evidence-informed clinical recommendations. RESULTS: Of 64 statements, 49 (76.6%) achieved consensus: 5 of 7 on the definition, 11 of 18 on diagnosis, 15 of 18 on patient assessment and 18 of 21 on treatment. Recommendations emphasize clinical diagnosis and long-term, individualized management; endorsed treatments include high-potency topical corticosteroids, calcineurin inhibitors, topical JAK inhibitors, phototherapy and-off-label in most settings-selected systemic agents for refractory disease. The recommendations also highlight critical gaps, notably the need to develop and validate NE tailored patient assessment tools and to conduct large, well-designed clinical trials to establish the efficacy and safety of systemic therapies for NE, as well as defining specific treatment response targets. CONCLUSIONS: These are the first expert consensus recommendations to provide a comprehensive framework for the diagnosis and management of NE in clinical practice. They offer practical, evidence-informed guidance to improve care for this underappreciated condition. Priority gaps include validated NE-specific assessment tools and randomized trials of systemic therapies.
引用
- Deleuran M, Eyerich K, de Bruin-Weller M, et al. European consensus recommendations for nummular eczema: A modified Delphi study. J Eur Acad Dermatol Venereol. 2026. PMID: 42411804. doi:10.1111/jdv.70560
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。